CJC-1295 (DAC)
CJC-1295 with DAC is a long-acting GHRH analog peptide that promotes growth hormone release.
We have not published an audit on CJC-1295 (DAC). Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
CJC-1295 with DAC binds to circulating albumin, which shields it from breakdown and extends its half-life to about 6-8 days, allowing for sustained signaling to the pituitary gland to release growth hormone. [Source: Peptide Dosing Protocols]
CJC-1295 with DAC is a modified growth hormone-releasing peptide that binds to albumin in the blood, which keeps it active for about 6-8 days per injection, during which it continuously signals the pituitary gland to release growth hormone and raise IGF-1 levels.
Reported side effects
The most commonly reported side effects include injection-site reactions (pain, redness, swelling, lumps), flushing, headache, nausea, water retention, and numbness or tingling, with side effects tending to be more frequent at higher doses and potentially lasting for days due to the long half-life.
Who should avoid it
People with active cancer, significant heart disease, diabetes, those who are pregnant or breastfeeding, anyone with a known peptide allergy, and anyone without qualified medical supervision should avoid CJC-1295 with DAC.
What gets monitored
IGF-1 (baseline, mid-cycle, and end of cycle), fasting glucose, HbA1c, blood pressure, and resting heart rate during cycles. [Source: Peptide Dosing Protocols]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for CJC-1295 (DAC) or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 1,000 mcg once weekly · Low: 500-1,000 mcg once weekly · High: 2,000 mcg once weekly or 1 mg twice weekly | once weekly8-12 weeks · 8-12 weeks on, 4-6 weeks off | Subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). Half-life: 6-8 days. Common research-planning ranges land between 1-2 mg subcutaneously once weekly. |
| DAC version referenced at 2-3 mg per dose; extended half-life supports infrequent dosing. Bedtime administration cited to align with sleep-phase GH release. | 1-2x weekly · Optionally before bedOn-cycle 8-12 weeks, off-cycle 6-12 weeks | subcutaneous | Peptide Therapy Reference Text, internal KB v4What it saysHide(Aug 2026), secondary reference; provider confirmation required. |
- once weekly8-12 weeks · 8-12 weeks on, 4-6 weeks off
- Subcutaneous injection
- Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). Half-life: 6-8 days. Common research-planning ranges land between 1-2 mg subcutaneously once weekly.
- 1-2x weekly · Optionally before bedOn-cycle 8-12 weeks, off-cycle 6-12 weeks
- subcutaneous
- Peptide Therapy Reference Text, internal KB v4
What it saysHide
(Aug 2026), secondary reference; provider confirmation required.
- reconstitute lyophilized powder with bacteriostatic water before use
Common questions
What is the starting dose of CJC-1295 with DAC?
Most research-planning protocols start at 500-1,000 mcg (0.5-1 mg) once weekly by subcutaneous injection.
What is CJC-1295 with DAC's half-life?
Estimated half-life is approximately 5.8-8.1 days.
What results were reported in CJC-1295 with DAC trials?
Phase 1 data reported growth hormone elevation roughly 2-10 fold and IGF-1 elevation 1.5-3 fold.
How is CJC-1295 with DAC reconstituted?
A 10 mg vial reconstituted with 3.0 mL bacteriostatic water yields about 3,333 mcg/mL.
Check 10 mg in 3 mL in the calculator →Is CJC-1295 with DAC FDA-approved?
No, as of June 2026, CJC-1295 with DAC is not FDA-approved.
What are the most common side effects?
Most reported effects include injection-site reactions, flushing, headache, GI symptoms, and water retention.
How does CJC-1295 with DAC compare to CJC-1295 No DAC?
Receptor activity is essentially identical, but DAC extends the half-life to 6-8 days.
What vial sizes are available for CJC-1295 with DAC?
This page's planning math assumes a 10 mg research vial.
Sources
The reference sections above are imported from our compound knowledge base, which classes the evidence for CJC-1295 (DAC) as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.
Peptide bioregulator referenced for connective tissue support.
Peptide bioregulator referenced for nervous system support.
Combination research blend of CJC-1295 (no DAC) and Ipamorelin. Studied as a GHRH/GHRP combination in growth-hormone-axis research.
Peptide bioregulator referenced for pineal support.